Progen's lead cell proliferation product, PG11047, targets hyper-proliferating cells specifically to inhibit tumor growth, and is currently undergoing two phase 1 clinical trials.
The pre-clinical research presented at the Conference showed the product provides a significant additive anti-cancer effect when combined with Cisplatin and Avastin when compared with either drug alone in lung cancer and prostate cancer models respectively.
Progen is currently progressing PG11047 through early clinical development in parallel to additional translational studies to determine the most promising indications.
Mr Homburg said to date, 44 patients had been treated in the monotherapy PG11047 Phase 1 trial, and over 130 patients in combination studies with approved anti-cancer therapies. The dosing regime in the monotherapy trial has been escalated far beyond Progen's original expectations.
"While we expect to find the maximum dose soon, we already have supporting data that the drug will have a large therapeutic window when given as a monotherapy," he said.
Mr Homburg said the latest findings in Progen's epigenetics and cell proliferation technologies represented another important milestone in the development of its anti-cancer portfolio.
"These latest findings prove we have the technology, the expertise and the resources to progress our strong product pipeline," he said.
"We have a fantastic team of collaborators, who have played a significant role in these achievements.
"We are very pleased to have had the opportunity to present these findings on the world stage, among leaders of the international scientific community."
Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, developme
|SOURCE Progen Pharmaceuticals Limited|
Copyright©2009 PR Newswire.
All rights reserved